NSE · ORCHPHARMA
Orchid Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹304 Cr with net profit ₹12 Cr — a 3.93% net margin, versus 0.78% the period before.
Shareholding
As of 2026-09-30
- Promoter74.45%
- Public7.18%
- FII0.93%
- DII17.44%
33,790 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.38× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #35 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Orchid Pharma Limited(this company) | ₹5,198 Cr | 287.42 | 3.32 | 1.34% | 1% |
AI analysis
AI-generated · google/gemini-2.5-flashOrchid Pharma Limited trades on the Indian markets with a market capitalization of Rs 5308 Cr. The company reported revenue of Rs 949.4 Cr and a net profit of Rs 99.6568 Cr for the year ending Mar 2025. Its 52-week high was Rs 1119.8 and its 52-week low was Rs 480.
Positives
- +The company's profit margin is high at 250.9%.
- +Return on equity (ROE) is 210.6%.
- +The debt-to-equity ratio is low at 0.13.
- +Promoter holding is substantial at 69.8355% as of March 31, 2026.
Negatives
- −Return on capital employed (ROCE) is low at 2.4751%.
- −The dividend yield is 0%.
- −Net profit in Dec 2025 was negative at -Rs 12.61 Cr.
- −The December 2025 quarter reported negative EBITDA of -Rs 1.86 Cr.
- −The company is under LT-ASM and ASM 1 surveillance.
Financial Performance
For the financial year ending March 2025, Orchid Pharma Limited generated a revenue of Rs 949.4 Cr. The annualized revenue growth stood at 12.5%. The company's net profit margin was 250.9%, leading to a profit of Rs 99.6568 Cr for the same period. Earnings per share (EPS) for the year ending Mar 2025 were Rs 19.65.
Profitability & Returns
The company's profit margin was 250.9%. Return on equity (ROE) was 210.6%, while return on capital employed (ROCE) was 2.4751%. The earnings per share (EPS) is reported at Rs 5.35.
Balance Sheet
Orchid Pharma Limited has a debt-to-equity ratio of 0.13, indicating a low level of debt relative to its equity. The book value per share is Rs 253.91.
Ownership & Pledges
As of March 31, 2026, promoters held 69.8355% of the shares. Public shareholding was 9.0463%, while domestic institutional investors (DIIs) held 20.2484%. Foreign institutional investors (FIIs) held 0.8698% of the company's shares. The total number of shareholders was 35118.
Regulatory & Surveillance
Orchid Pharma Limited is under LT-ASM and ASM 1 surveillance measures. No pledges against promoter shareholding were reported as of the latest available data.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.